SEC Form 4 · accession 0000899243-16-021559
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John G. Aunins
Officer — Chief Technology Officer & EVP
Period of report
May 31, 2016
Accepted (ET)
Jun 2, 2016 · 9:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | May 31, 2016 | S | 13,365 | $30.02 | D | 42,695 | D | |
| Common StockF3 | May 31, 2016 | S | 650 | $30.57 | D | 42,045 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2016.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $29.46 to $30.44. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $30.50 to $30.62. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.